Bilgetekin, I. Et Al. 2021. The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15 .

Bilgetekin, I., Dogan, M., Karacin, C., Basal, F. B., Esin, E., Ucar, G., ... Isak, O. A.(2021). The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

Bilgetekin, Irem Et Al. "The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Bilgetekin, Irem Et Al. "The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021

Bilgetekin, I. Et Al. (2021) . "The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15.

@article{article, author={Irem Bilgetekin Et Al. }, title={The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}